{"schema_version":"secwatch.filing_event.v1","accession":"0002007919-26-000047","form_type":"8-K","ticker":"INBX","cik":"0002007919","company_name":"Inhibrx Biosciences, Inc.","filed_at":"2026-09-08T20:01:51+00:00","discovered_at":"2026-09-08T20:03:00.739654+00:00","generated_at":"2026-09-08T20:03:20.766680+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Inhibrx INBRX-106 nearly doubles cORR in Phase 2 HNSCC; PFS 9.6 vs 4.9 months","bullets":["cORR 48.3% (INBRX-106+pembro) vs 26.5% (pembro alone); CR 13.8% vs 0%.","Median PFS 9.6 vs 4.9 months; 6-mo PFS 72.4% vs 42.8%.","HPV+ subgroup: cORR 80% vs 33.3%, CR 30% vs 0%, PFS6 90% vs 33%.","Plans to expand Phase 2 by ~50 HPV+ OPSCC patients; Phase 3 as confirmatory.","Combination manageable; common AEs rash, fatigue, diarrhea (low grade)."],"urls":{"canonical":"https://secwatch.observer/filing/0002007919-26-000047","json":"https://secwatch.observer/filing/0002007919-26-000047.json","markdown":"https://secwatch.observer/filing/0002007919-26-000047.md","text":"https://secwatch.observer/filing/0002007919-26-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000047/0002007919-26-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000047/inhibrx-20260908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T20:03:20.766680+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}